Hansa Biopharma Reports Third Quarter and Interim Year to Date 2026 Financial Results

Closing of the €115 million licensing transaction with SERB Cash and cash equivalents amounted to 1,337.2 MSEK as of 30 September 2026 The first commercial patient in Australia received a living-donor kidney transplant following treatment with Idefirix (Imlifidase) LUND, Sweden, Nov. 11,...

Published on The Global News Feed

11 Nov 2026, 06:43 UTC